CClinicalTrials.gg
CompletedNCT02692664TAILORUpdated Feb 17, 2026

Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft

An observational study in Iliac Aneurysm and AAA, sponsored by JOTEC GmbH. Completed at 2 sites in France. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by JOTEC GmbH · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
71
Ages
19 Years and older
Sex
All
01

Study summary

In this study, patients will be observed who receive an E-liac Stent Graft for treatment of isolated iliac aneurysms or an E-liac Stent Graft in combination with one of the following AAA stent grafts: E-tegra Stent Graft, Endurant AAA Stent Graft, Zenith AAA Endovascular Graft, Gore Excluder AAA Endoprosthesis for treatment of aorto-iliac aneurysms.

Objectives of this post-market registry are:

Primary: To prevent the risk of rupture and death by the treatment of common iliac aneurysm with an iliac branched stent graft (E-liac, JOTEC) Secondary: Evaluation of safety and feasibility of the E-liac Stent Graft System used in endovascular treatment of uni- or bilateral aorto-iliac or iliac aneurysm.

02

Conditions studied

  • Iliac Aneurysm
  • AAA

Browse trials for

Keywords

  • iliac side branch
03

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female patients with unilateral or bilateral common iliac aneurysm, treated with the E-liac Stent Graft System

Inclusion criteria

  • Unilateral or bilateral aorto-iliac or iliac aneurysm
  • Suitable for endovascular repair
  • Patient must be compliant with life- long follow-up investigations
  • >18 years old
  • lliac/femoral access vessel morphology compatible with the implantation procedure and the 18Fr (6mm OD) delivery system
  • Non-aneurysmal common iliac artery landing area in case of iliac artery aneurysm ≥ 20mm
  • Diameter of the common iliac artery in the proximal landing area: 12mm to 17mm
  • Non-aneurysmal external iliac artery segment distal to the aneurysm ≥15mm
  • Diameter of the external iliac artery in the distal landing area: 8mm to 13mm
  • Non-aneurysmal internal iliac artery segment distal to the aneurysm ≥15mm
  • Angle between external iliac artery and internal iliac artery ≤50°
  • Thrombus free iliac lumen in the area of iliac bifurcation to open hypogastric side branch and to implant covered stent ≥18mm
  • Sufficiently open internal iliac arterv ostium
  • Patients must comply with the instructions for use.
  • Patients with common iliac aneurysm with a diameter ≥30mm when isolated or common iliac aneurysm with a diameter >25mm when associated with an abdominal aortic aneurysm
  • Unilateral or bilateral common iliac aneurysm
  • Patient's anatomy must be fit for stent graft placement on preoperative angio CT scan.
  • Patient is affiliated to the social security or equivalent system.
  • The patient must be available for the appropriate follow-up times for the duration of the study.
  • Patient has been informed of the nature of the study, agrees to its provisions and has signed the informed consent from.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not meet the instructions for use
  • Patients with one of the contraindications as indicated in the instructions for use
  • Patients with a stenotic internal iliac ostium of \< 4mm in Diameter
  • Patients with severe internal iliac atherosclerosis
  • Patients that do not have a suitable landing area in the main stem of the IIA (maximum diameter in landing area \<12mm)
  • Patients with pseudoaneurysms
  • Patients with symptomatic and ruptured iliac aneurysms
  • Patients pretreated with a AAA stent graft or a bifurcated vascular graft
  • Patient with thrombocytopenia
  • Patient with an estimated glomerular filtration rate \< 30 ml/min/1,73m2 immediately before the Intervention
  • Female of child bearing potential
  • In the lnvestigator's opinion patient has (a) eo-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements, or impact the scientific integrity of the study
  • Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints
  • Patient with malignancy needing chemotherapy or radiation
  • Patients with life expectancy of less than 36 months
  • Patient minor or under guardianship
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
71 participants (actual)
Patient registry
No

Interventions

  • DeviceEndovascular aorto-iliac repair

    Also known as: EVAR

05

What researchers measure

Primary outcomes

  1. Clinical success

    Clinical success related to the E-liac Stent Graft combines the following criteria (adapted from Chaikof 2002): * Clinical success should be reported on an intent-to-treat Basis * requires successful deployment of the E-liac Stent Graft at the intended location without * Death as a result of iliac aneurysm-related treatment * Type I or III endoleak * E-liac Stent Graft infection * E-liac Stent Graft thrombosis (including internal iliac artery thrombosis) * Aneurysm growth \>3mm in maximum diameter for common iliac aneurysm and \>5mm in maximum diameter for aortic aneurysm at 12, 24, and 36 months follow-up * Common iliac aneurysm rupture * Conversion to open repair * Failure of E-liac Stent Graft integrity

    Time frame: 30 days follow-up

06

Study locations

2 sites
  • CHU Nantes
    Nantes, France
  • CHU Rennes
    Rennes, France
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT02692664
Lead sponsor
JOTEC GmbH
Responsible party
Sponsor
First posted
Feb 26, 2016
Start date
May 1, 2016
Primary completion
Jul 5, 2024
Completion
Jul 5, 2024
Last update
Feb 17, 2026

Study contacts

Adrien Kaladji, Prof.
principal investigator · Rennes University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion